Stock Events

Stock Events

Oncolytics Biotech 

$0.9
80
+$0+0% Today

Statistics

Day High
0.93
Day Low
0.9
52W High
1.51
52W Low
0.33
Volume
250,860
Avg. Volume
1,377,150
Mkt Cap
93.27M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

1MayExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.1
-0.08
-0.06
-0.05
Expected EPS
-0.04553136036
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-45.07MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ONCY. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is involved in developing oncology treatments, including oncolytic virus therapies, directly competing with Oncolytics Biotech's approach to cancer treatment.
Merck
MRK
Mkt Cap298.84B
Merck's extensive portfolio in oncology, including immunotherapy treatments, positions it as a competitor in the cancer treatment space, overlapping with Oncolytics Biotech's market.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb offers a range of cancer treatments, including immunotherapies that compete with Oncolytics Biotech's viral-based cancer therapies.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, with its focus on oncology and viral treatments, competes in the same space as Oncolytics Biotech, especially in the development of innovative cancer therapies.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a broad oncology division, including the development of treatments that could compete with Oncolytics Biotech's oncolytic virus therapy approach.
Novavax
NVAX
Mkt Cap1.25B
Novavax, while primarily known for vaccines, is exploring cancer vaccine treatments that could potentially compete with Oncolytics Biotech's viral-based therapies.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, develops a variety of oncology treatments that could compete with Oncolytics Biotech's approach to cancer therapy.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals focuses on developing monoclonal antibodies for cancer treatment, a method that could be seen as complementary or competitive to Oncolytics Biotech's viral therapies.
Sorrento Therapeutics
SRNE
Mkt Cap1.76M
Sorrento Therapeutics is involved in the development of new therapies for cancer, including approaches that could compete with or complement Oncolytics Biotech's oncolytic virus strategy.
Vir Biotechnology
VIR
Mkt Cap1.45B
Vir Biotechnology, while focusing on infectious diseases, is exploring the potential of using viral vectors for therapeutic purposes, which could intersect with Oncolytics Biotech's cancer treatment strategies.

About

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Show more...
CEO
Mr. Kirk J. Look C.A., CPA
Employees
28
Country
US
ISIN
CA6823108759

Listings

BOATS
BOATS
ONCY.BOATS
XNAS
US
ONCY

1 Comments

toosie

one of my best investments

11
Rambo

And one my worst, keeps going down for the last year. Dropped over $105 in 6 months.

1
Me Medesimo

If you don't mention the percentage, it's a comment from a stock market newbie.

3
Rambo

31%. Happy now?

5

FAQ

What is Oncolytics Biotech stock price today?▼
The current price of ONCY is $0.9 USD — it has increased by +0% in the past 24 hours. Watch Oncolytics Biotech stock price performance more closely on the chart.
What is Oncolytics Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oncolytics Biotech stocks are traded under the ticker ONCY.
Is Oncolytics Biotech stock price growing?▼
ONCY stock has fallen by -3.24% compared to the previous week, the month change is a -15.09% fall, over the last year Oncolytics Biotech has showed a +83.67% increase.
What is Oncolytics Biotech market cap?▼
Today Oncolytics Biotech has the market capitalization of 93.27M
When is the next Oncolytics Biotech earnings date?▼
Oncolytics Biotech is going to release the next earnings report on May 01, 2026.
What were Oncolytics Biotech earnings last quarter?▼
ONCY earnings for the last quarter are -0.1 USD per share, whereas the estimation was -0.06 USD resulting in a -63.19% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oncolytics Biotech revenue for the last year?▼
Oncolytics Biotech revenue for the last year amounts to 0 USD.
What is Oncolytics Biotech net income for the last year?▼
ONCY net income for the last year is -45.07M USD.
How many employees does Oncolytics Biotech have?▼
As of April 08, 2026, the company has 28 employees.
In which sector is Oncolytics Biotech located?▼
Oncolytics Biotech operates in the Health Care sector.
When did Oncolytics Biotech complete a stock split?▼
The last stock split for Oncolytics Biotech was on May 25, 2018 with a ratio of 1:9.5.
Where is Oncolytics Biotech headquartered?▼
Oncolytics Biotech is headquartered in Calgary, US.